2023-06-07 10:50:34 ET
scPharmaceuticals ( NASDAQ: SCPH ) lost ~9% in the morning hours Wednesday after issuing an update on the commercial rollout of its recently launched heart failure therapy Furoscix.
Ahead of a presentation at a healthcare conference, scPharma ( SCPH ) disclosed in a regulatory filing the demand and supply data related to Furoscix sales from February to May.
In October, the FDA approved Furoscix for subcutaneous use as a treatment for heart failure congestion, and the company launched the product in mid-February.
According to an 8-K filing, scPharma ( SCPH ) has shipped Furoscix doses for about 230 prescriptions in May out of ~440 prescriptions written for the month.
Out of about 290, 280, and 40 prescriptions written, the company has delivered Furoscix doses for approximately 150 prescriptions each for April and March and ten prescriptions for February, respectively.
More on scPharma
- FDA approves scPharmaceuticals Furoscix to treat congestion in heart failure
- scPharmaceuticals stock surges ~20% amid Q4 results with eye on Furoscix future revenue
- scPharmaceuticals: Furoscix Firing On All Cylinders In Q1, Bullish Than Ever
For further details see:
scPharma slips after sales update on heart failure drug